The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
ORGANIZATION
JGA Suspends Kyowa Pharma for 5 Years after GMP Violations
The Japan Generic Medicines Association (JGA) said on April 22 that it has suspended the membership of Kyowa Pharmaceutical Industry for five years, after the company was slapped with business suspension orders over GMP violations. The suspension will last from…
To read the full story
Related Article
- Kyowa Pharma Reveals Fudged Accelerated Stability Test of Mestinon
April 17, 2024
- Kyowa Pharma Hit by Biz Suspension over Manufacturing Flaws, Record Fabrications
March 29, 2022
- Kyowa Pharma to Face Biz Suspension Order over Manufacturing Flaws
March 23, 2022
- Kyowa to Resume Alfacalcidol Shipments in Mid-Sept.; MHLW Urges Priority for Patients without Alternative Therapies
September 2, 2021
ORGANIZATION
- JGA Targets FY2027 for Resolving Drug Shortages, Two Years Ahead of Forecast
June 20, 2025
- Generic Use Rate at 89.0% in January: Payer
June 18, 2025
- JMA’s Upper House Candidate Says Scraping Drug Prices to Pool Resources No Longer Holds
June 17, 2025
- 84% of Pharmacies See More Generic Dispensing after Rollout of New LLP Rule: FPMAJ
June 17, 2025
- FPMAJ Calls for Relaxation of Support Rules for Low-Priced Drugs
June 17, 2025
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…